Blood samples do not always reach the laboratory in perfect condition. Rough handling, delayed processing, improper needle size, or incorrect storage can rupture red blood cells and create hemolyzed specimens. When this occurs, intracellular contents spill into plasma or serum and disrupt many routine and specialized assays. Hemolysis is one of the most common preanalytical problems and a leading cause of sample rejection. For clinicians, bioanalytical scientists, and DMPK teams, understanding how hemolyzed blood alters results is essential to protect diagnostic accuracy, study timelines, and data integrity.
What Happens at the Cellular Level During Hemolysis?
Hemolysis damages red blood cell membranes, causing them to rupture. Their intracellular contents, especially hemoglobin and electrolytes, leak into the surrounding plasma or serum and trigger multiple chemical and optical changes.
Breakdown of Red Blood Cells and Release of Intracellular Components
During hemolysis, mechanical stress, osmotic shifts, or temperature extremes break red blood cell membranes. This lysis releases large amounts of hemoglobin, potassium, lactate dehydrogenase (LDH), AST, and other enzymes into plasma or serum. Free hemoglobin can bind nitric oxide and modify redox balance. Cellular debris and membrane fragments increase sample turbidity. The sudden release of intracellular ions and proteins artificially elevates their measured concentrations outside cells. These shifts do not reflect the patient’s true physiology, but rather the damage that occurred during blood draw, handling, or processing.
Changes in Plasma Composition and Visible Sample Appearance
As hemolysis progresses, plasma or serum changes both chemically and visually. Free hemoglobin colors the supernatant pink to dark red, depending on severity. The transparent, straw-yellow appearance of normal plasma becomes tinted and often more opaque. Potassium, phosphate, and intracellular enzymes rise markedly, while dilution effects and chemical interactions can lower other analytes. Light scattering from cell fragments distorts photometric readings. These changes alter sample indices that modern analyzers use to flag hemolysis. Technologists can often see hemolysis directly, but mild cases may only be detected instrumentally.
How Does Hemolyzed Blood Affect Laboratory Results and Bioanalysis?
hemolyzed blood can skew many laboratory measurements. It interferes with analytical methods, alters biomarker concentrations, and undermines pharmacokinetic and pharmacodynamic assessments that support drug development and regulatory submissions.
Interference with Biochemical Assays and Analytical Methods
Free hemoglobin strongly absorbs light across multiple wavelengths, so spectrophotometric and colorimetric assays often give biased results. Hemolysis increases sample turbidity, which changes light scattering and affects endpoint and kinetic readings. Enzymes released from red cells can continue catalyzing reactions in vitro and distort assay kinetics. Hemoglobin may also bind or oxidize analytes and reagents, affecting calibration curves and internal standards. Immunoassays can suffer from non‑specific binding or matrix effects in hemolyzed samples. Altogether, these issues lower assay precision, accuracy, and reportable range unless laboratories apply strict rejection or correction criteria.
False Elevation or Suppression of Key Biomarkers
Hemolysis tends to falsely raise markers abundant in erythrocytes, such as potassium, LDH, AST, ALT (to a lesser degree), and plasma-free hemoglobin. Clinicians may see apparent hyperkalemia or liver injury that does not reflect reality. At the same time, hemolysis can falsely suppress some analytes. Dilution, chemical degradation, or assay interference may lower measured haptoglobin, troponin, or certain hormones and drugs. This combination of pseudo‑elevations and pseudo‑reductions complicates interpretation. Without a clear notation of hemolysis status, providers and scientists risk over‑treating, under‑treating, or misclassifying patient conditions and study outcomes.
Impact on DMPK Studies and Drug Development Data Integrity
Drug metabolism and pharmacokinetic (DMPK) studies rely on accurate concentration–time profiles. Hemolyzed samples can alter measured drug levels if compounds or metabolites partition into red cells or bind hemoglobin. Enzymes released from erythrocytes may metabolize labile drugs ex vivo, changing apparent clearance or half‑life. Matrix effects from hemoglobin and cell debris also disturb LC–MS/MS response and internal standard performance. If teams do not identify and manage hemolyzed specimens, bioanalytical variability increases and key parameters, like Cmax and AUC, become unreliable, threatening model development, decision making, and regulatory confidence.
Consequences of Hemolyzed Samples in Clinical and Research Settings
Hemolyzed samples create real-world problems. They can cause diagnostic errors, trigger unnecessary interventions, delay reporting, and increase operational costs in clinical laboratories, clinical trials, and nonclinical research programs.
Diagnostic Errors, Misinterpretation, and Clinical Risks
Clinicians may diagnose hyperkalemia, hemolytic anemia, hepatic injury, or myocardial damage based on results distorted by hemolysis. Apparent potassium spikes from in‑vitro hemolysis can lead to unnecessary ECG monitoring, repeat testing, or inappropriate treatment. Masked elevations or false low values may delay recognition of real disease. If reports fail to flag hemolysis or staff overlook comments, misinterpretation becomes more likely. These errors pose direct risks to patient safety, from needless anxiety and procedures to missed diagnoses. Robust preanalytical controls and clear communication remain vital safeguards.
Sample Rejection, Delays, and Increased Study Costs
Laboratories often reject moderate to severely hemolyzed specimens to protect quality. Each rejection means additional venipuncture, patient inconvenience, and lost time. For hospitalized patients, delays in critical tests can slow clinical decisions. In clinical trials and nonclinical studies, hemolyzed samples may require recollection outside optimal time windows or lead to missing data points. Sponsors then face protocol deviations, extended recruitment, and higher monitoring costs. Processing and investigating hemolyzed samples also consume staff resources. Preventing hemolysis upstream is usually far cheaper than dealing with downstream consequences.
Conclusion
Hemolyzed blood samples reflect damage that occurs after collection, not necessarily disease within the body. When red blood cells lyse, they release hemoglobin, electrolytes, and enzymes that alter plasma composition and distort many assays. These changes can create false biomarker elevations or reductions, compromise DMPK analyses, and trigger diagnostic errors. Laboratories and research teams must recognize, evaluate, and manage hemolyzed specimens carefully to protect data integrity. By improving collection techniques, handling, and preanalytical oversight, organizations can reduce hemolysis and safeguard both patient care and study outcomes.
